ClearPoint Neuro Past Earnings Performance
Past criteria checks 0/6
ClearPoint Neuro's earnings have been declining at an average annual rate of -26.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 20.5% per year.
Key information
-26.9%
Earnings growth rate
-15.0%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 20.5% |
Return on equity | -62.6% |
Net Margin | -59.6% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Dec 10Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Sep 14Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Aug 16Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
Jul 11ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 09ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro: Continuous Great Execution
Sep 19ClearPoint Neuro: Picks & Shovels Galore
Aug 19ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
Jul 25ClearPoint Neuro: Continuous Execution Despite Covid Headwind
May 20Revenue & Expenses Breakdown
How ClearPoint Neuro makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 30 | -18 | 26 | 12 |
30 Jun 24 | 28 | -18 | 25 | 11 |
31 Mar 24 | 26 | -21 | 25 | 11 |
31 Dec 23 | 24 | -22 | 24 | 12 |
30 Sep 23 | 22 | -22 | 23 | 12 |
30 Jun 23 | 22 | -21 | 22 | 12 |
31 Mar 23 | 21 | -18 | 21 | 11 |
31 Dec 22 | 21 | -16 | 19 | 11 |
30 Sep 22 | 20 | -16 | 18 | 11 |
30 Jun 22 | 19 | -16 | 18 | 11 |
31 Mar 22 | 17 | -16 | 16 | 11 |
31 Dec 21 | 16 | -14 | 15 | 9 |
30 Sep 21 | 16 | -12 | 14 | 8 |
30 Jun 21 | 15 | -9 | 13 | 7 |
31 Mar 21 | 14 | -7 | 11 | 5 |
31 Dec 20 | 13 | -7 | 11 | 5 |
30 Sep 20 | 12 | -7 | 10 | 4 |
30 Jun 20 | 12 | -6 | 10 | 3 |
31 Mar 20 | 12 | -6 | 10 | 3 |
31 Dec 19 | 11 | -6 | 9 | 3 |
30 Sep 19 | 10 | -5 | 8 | 3 |
30 Jun 19 | 9 | -5 | 8 | 2 |
31 Mar 19 | 8 | -6 | 8 | 2 |
31 Dec 18 | 7 | -6 | 8 | 2 |
30 Sep 18 | 7 | -7 | 8 | 2 |
30 Jun 18 | 7 | -7 | 8 | 2 |
31 Mar 18 | 7 | -7 | 8 | 3 |
31 Dec 17 | 7 | -7 | 8 | 3 |
30 Sep 17 | 7 | -7 | 8 | 3 |
30 Jun 17 | 7 | -8 | 8 | 3 |
31 Mar 17 | 6 | -8 | 8 | 3 |
31 Dec 16 | 6 | -8 | 8 | 3 |
30 Sep 16 | 6 | -8 | 8 | 3 |
30 Jun 16 | 5 | -5 | 8 | 2 |
31 Mar 16 | 5 | -7 | 8 | 2 |
31 Dec 15 | 5 | -8 | 8 | 2 |
30 Sep 15 | 4 | -9 | 9 | 2 |
30 Jun 15 | 3 | -13 | 9 | 3 |
31 Mar 15 | 4 | -11 | 9 | 3 |
31 Dec 14 | 4 | -5 | 8 | 3 |
30 Sep 14 | 4 | -4 | 8 | 3 |
30 Jun 14 | 4 | -4 | 7 | 3 |
31 Mar 14 | 3 | -4 | 7 | 3 |
31 Dec 13 | 4 | -7 | 7 | 3 |
Quality Earnings: CLPT is currently unprofitable.
Growing Profit Margin: CLPT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLPT is unprofitable, and losses have increased over the past 5 years at a rate of 26.9% per year.
Accelerating Growth: Unable to compare CLPT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLPT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: CLPT has a negative Return on Equity (-62.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 11:22 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ClearPoint Neuro, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Andrew D'Silva | B. Riley Securities, Inc. |
Kyle Bauser | B. Riley Securities, Inc. |
Sally Yanchus | Brookline Capital Markets |